SP-0506: How do we select meaningful pre-clinical models for studies in radiation biology?  by De Ruysscher, D.
ESTRO 35 2016                                                                                                                                                    S239 
______________________________________________________________________________________________________ 
protocols under experimental conditions. Our laboratory is 
developing an in vivo radiobiology research program using the 
small animal radiotherapy research platform (SARRP, Xstrahl 
Life Sciences) as a central enabling technology to perform 
translational studies focussing on biologically optimised 
radiotherapy, nanoparticle theranostics and novel 
combination treatments. A major challenge now facing 
investigators is how to correctly apply the technology to 
accurately model clinical scenarios in relevant small animal 
models so that it can be exploited to its full potential in 
driving translational studies with outcomes likely to impact 
current standard of care in radiation oncology.  
An overview of the current state-of-the-art in preclinical 
radiotherapy will be presented including recent 
developments such as integration of bioluminescence 
imaging, preclinical 4-D CBCT and Monte Carlo based dose 
calculation methods. Examples of innovative preclinical 
studies will be highlighted along with experience from our 
own laboratory from commissioning to experimental design 
and important considerations for the successful execution of 
hypothesis-driven investigations using small animal 
radiotherapy.  
Despite certain challenges, small animal radiotherapy has 
much potential to bridge the translational gap between basic 
radiobiology and radiotherapy. As the technology develops 
and investigators gain experience as multidisciplinary 
scientists, pre-clinical studies that increasingly replicate the 
clinical scenario will drive new approaches in radiobiology 
that should ultimately translate to human health gains. 
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Although advances with in-vitro cancer cell culture models 
have occurred recently, in vivo tumor models are still crucial 
for the study of novel radiation treatments. This is 
particularly important for radiation combination approaches 
that target tumor cell non-autonomous anti-cancer pathways 
such as the tumor microenvironment or the immune system. 
In addition, more sophisticated animal studies with radiation 
are now possible with the advent of technologies that 
integrate treatment planning, imaging, and radiation delivery 
capabilities such as with the small-animal radiation platform 
(SARRP; Fig 1).  
 
 
Tumor xenograft models using human-derived tumor models 
implanted into immune-deficient mice are a mainstay of pre-
clinical testing and discovery. Although the majority of in 
vivo studies involve immunocompromised mice, such as 
athymic, severe combined immune-deficiency (SCID) or NOD-
SCID mice, these models are less ideal with radiation studies 
because some of these mice have mutations in DNA response 
and repair pathways. The abnormal DNA repair mechanisms 
in these mice limit the applicability of results with 
radiosensitizers given the integral role of DNA damage to the 
biologic effect of radiation therapy. Furthermore, anti-tumor 
effects of radiation may be mediated by the immune system. 
As a result of these limitations, genetically engineered mouse 
models (GEMMs) are becoming more widely used in 
preclinical studies with and without radiation. “Co-clinical 
trials” that use GEMMs that faithfully replicate the 
mutational events observed in human cancers to conduct 
preclinical trials that parallel ongoing human phase I/II 
clinical trials have shown great promise in cancer. This 
presentation will review published and on-going pre-clinical 
studies targeting both cancer cell autonomous and cancer 
cell non-autonomous pathways utilizing the SARRP with both 
xenograft tumor models and GEMMs at Johns Hopkins.  
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Clinical research faces many problems, of which the 
availability of pre-clinical models that predict the human 
situation is one of the most important. Pre-clinical tumour 
models are being used for decades in many cases with the 
assumption that they are predictive for what will later 
happen in humans. As such, the use of pre-clinical, mostly 
mouse, models may limit the exposure of inactive and or 
toxic treatments in patients. Although there is no doubt that 
pre-clinical models have been crucial to understand better 
molecular and other characteristics of carcinogenesis, growth 
and metastases and were the basis of many currently used 
cancer therapies, they still have considerable shortcomings. 
Classical mouse models use tumour cell lines that have been 
grown in vitro for many years and hence may have altered 
characteristics compared to de novo tumours. These tumour 
cells are then implanted subcutaneously in mice and tend to 
grow rapidly and thus do not mimic the much slower doubling 
times of most human cancers. This faster tumour growth may 
lead to a higher sensitivity for most chemotherapy drugs and 
hence erroneous conclusions. Moreover, in some situations, 
ectopic (out of the normal place) subcutaneously implanted 
tumours — still a standard methodology — may respond 
differently to treatment compared to tumours grown in an 
orthotopic site, i.e. in their organ or tissue of origin, such as 
breast cancers in mammary fat pads. The latter may 
correspond more to the human situation. Moreover, 
metastases frequently show other responses than primary 
tumours in patients, and it is only recently that these effects 
can be mimicked in genetically engineered mouse models. 
Tumour bearing mice are often treated with drugs at levels, 
or with pharmacokinetics, that are not relevant to humans. 
Furthermore, nearly all pre-clinical models have not used 
tumours that were pre-exposed to another therapy, whereas 
in many phase I and phase II clinical trials only patients that 
show tumour progression after one or more systemic 
treatments are included. With the huge interest in immune 
therapy, the use of humanised mice has gained even more 
attention than before. However, these models still face 
problems with remaining mouse innate immunity and weak 
human innate and adaptive immunity. Even the best models 
suffer from the development of wasting disease in highly 
engrafted humanized mice and poorly developed lymph nodes 
and germinal centres. It is also unclear if the cell trafficking 
resembles that of humans.At present, no single mouse models 
mimics perfectly the human situation. However, models that 
use injected tumour cells in the organ from which they were 
derived and which form metastases in organs that are similar 
to the human situation may be the most appropriate for they 
bear a micro-environment that resembles that of humans. 
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Spontaneously arising tumours, preferentially in older mice 
may represent an interesting model for immune therapy. 
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It is clear that the bladder as an organ has marked shape and 
positional variability due to its function of storing urine 
before the call of nature. This has obvious repercussions for 
pelvic radiotherapy depending on the intent of treatment 
particularly if the bladder itself is the radiotherapeutic 
target. As an organ-at-risk (OAR) this variability can be 
important and this can also impact on adjacent organs such 
as the prostate, rectum and uterus if these latter organs are 
being treated with radiotherapy. These adjacent pelvic 
organs can also deform the bladder. In addition the setup 
position of the patient either supine or prone can also 
influence on the day-to-day bladder position and shape. 
Furthermore the kidneys filtered continuously thus there will 
be steady filling of the bladder with a rate dependant on the 
hydration status of the patient during radiotherapy delivery. 
Other factors may also be crucial such as bladder capacity 
and function as well as disease extent if there is bladder 
cancer. Therefore the variability of the bladder size and 
shape is an important consideration for any pelvic 
radiotherapy. Many investigators have reported on the 
marked difference in filling of the bladder with variation in 
bladder size that may range up to 20 mm on different 
scanning times during a course of fractionated radiotherapy. 
For primary bladder radiotherapy, identification of the 
disease extent remains important as both the target and 
tissue of tolerance is the bladder itself. This can also impact 
on the manner in which the bladder fills in 3D and be 
distorted by invasive bladder disease. It can be difficult to 
maintain daily consistency of the 3D shape and size thus 
there are several methods developed to deal with this 
including treatment with either an empty or comfortably full 
bladder to initiating adaptive planning and image guided 
delivery methods. Fiducials have been used to better target 
the main disease for either boosting disease or to incorporate 
focal therapy strategies. These methods can also permit 
organ avoidance if the bladder is an OAR and it is critical to 
minimise dose to it due to poor bladder function and other 
clinical factors. If the bladder is not the target then it can 
perform a useful function with intended filling prior to 
radiotherapy in order to displace other pelvic organs such as 
the bowel from irradiation such as with treatment of the 
pelvic nodes. Thus patient and disease related factors will 
need to be carefully assessed for each case. All these 
methods including their rationale and effectiveness will be 
discussed for both situations of the bladder as a target and as 
an OAR. 
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Background: Implantation of fiducial markers for IGRT 
(Image Guided Radiation Therapy) of prostate cancer patients 
increases the treatment accuracy by prostate localization 
using two orthogonal X-rays images. However the precision of 
the treatment depends on the stability of the fiducial 
marker. The aim of this study was to evaluate the migration 
of fiducial markers during the whole radiotherapy of prostate 
cancer patients.  
 
Material and methods: An analysis of the intraprostatic 
fiducials migration during the treatment planning was done 
on a group of 45 patients on the basis on fusion of kV CBCT 
(performed during the first week of the treatment) and 
planning CT. The value of migration during the course of 
radiotherapy was done on a group of 20 patients treated 
within IGRT protocol on the basis on the fusion of kV CBCTs, 
performed weekly. The migration was defined as a shift 
between central points of markers, measured in three axis.  
 
Results: The average values of the GoldAnchor™ migration 
during the treatment planning were: 1.1 mm (SD=0.9 mm) in 
the superior-inferior (SI) direction, 0.5 mm (SD=0.6 mm) in 
the left-right (LR) direction and 1.1 mm (SD=1.2 mm) in the 
anterior-posterior (AP) direction. The mean value of the 
vector of shifts was 1.9 mm (SD=1.3 mm). The average values 
of the GoldAnchor™ migration during the course of 
radiotherapy were: 0.1 mm (SD=0.2 mm) in the superior-
inferior (SI) direction, 0.1 mm (SD=0.3 mm) in the left-right 
(LR) direction and 0.2 mm (SD=0.4 mm) in the anterior-
posterior (AP) direction. The mean value of the vector of 
shifts during the treatment was 0.3 mm (SD=0.5 mm).  
 
Conclusions: The analysis of the collected data showed that 
the marker shifts during the treatment planning seems to 
have no clinical significance and probably are related to the 
inaccuracy of the fusion of kV CBCT and planning CT. Position 
of the marker is stable during the whole course of 
radiotherapy. Therefore, IGRT based on GoldAnchor™ 
markers is safe and effective method of prostate cancer 
patient positioning. 
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Purpose: To comply a decision aid tool with the criteria of 
the International Patient Decision Aid Standards (IPDAS), it is 
mandatory to follow a systematic and iterative approach to; 
(a) understand patient’s and clinicians decisional needs, (b) 
create prototypical tools, (c) evaluate these prototypes with 
patients and clinicians and (d) use these results to improve 
the tool. We developed and validated a web-based decision 
aid (DA) for shared decision making in prostate cancer 
patients using this approach.  
Methods: A prototype of the tool was designed based on the 
input of an interdisciplinary group. Its clarity and 
acceptability was tested using a mixed method (interview 
and technology acceptance questionnaire; 5-Likert scale). 
The evaluation was performed with physicians (N=19) and 
patients (N= 16). Professionals from 5 academic and private 
hospitals (urologists, radiotherapists, specialized nurses and 
family doctors) gave their perspective about the patients’ 
decisional needs and validated the information about the 
treatment options, complications and outcomes. The 
included patients were treated with either external beam 
radiotherapy, brachytherapy or prostatectomy. Patients who 
choose not to be treated (active surveillance) were also 
included. The decisional needs were evaluated during an 
interview. Afterwards the patients’ were guided through the 
DA and asked to fill in a questionnaire to check the 
comprehensibility of the tool. A second group of patients 
(N=8) was included to assess the e-learning effect of the DA 
and to check if patients were able to use the DA alone 
(without coaching).  
 
Results: The results were considered to create a new version 
of the DA. Physicians mentioned the need of information 
about basic anatomy, contraindications, hospital specific 
figures, and psychological support. Patients reported that the 
